Adicet Bio Inc (LTS:0HX7)
$ 0.8937 0.0228 (2.65%) Market Cap: 75.50 Mil Enterprise Value: -108.37 Mil PE Ratio: 0 PB Ratio: 0.36 GF Score: 31/100

Adicet Bio Inc To Discuss ADI-001 Clinical Update Call Transcript

Jun 26, 2023 / 08:30PM GMT
Release Date Price: $4.8 (+8.76%)
Operator

Thanks, everyone, for joining us. On the call today from Adicet are Chen Schor, President and Executive Officer; Dr. Francesco Galimi, Chief Medical Officer; Nick Harvey, Chief Financial Officer; and Dr. Blake Aftab, Chief Scientific Officer.

Before we begin, I'd like to remind you that various remarks that we make on this call contain forward-looking statements that are made under the safe harbor provisions of the securities laws, including, but not limited to, express or implied statements regarding the potential safety, durability, tolerability and efficacy of ADI-001.

Due to progress of ADI-001 in patients with relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma, or NHL, including selection of a recommended Phase II dose, expectations regarding future discussions with regulators and regulatory filings for product candidates in the company's pipeline and timing for the potentially pivotal Phase II study of ADI-001 in post CAR T LBCL patients.

In addition to our prepared remarks, we may make forward-looking statements in response to questions, including, for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot